Our study shows that, in addition to its function on immune cells, the CXCL12/HMGB1 heterocomplex fine tune modulates CXCL12 activity on tumor cells, and suggests disruption of the complex as a novel therapeutic strategy for inhibiting cancer cell migration and invasion. The gene discussed is CXCL12; the disease is neoplasm.